Edition:
United Kingdom

Ipsen And Exelixis Announce Phase 3 Trial Results Of Cabozantinib Showing Benefit In Hepatocellular Carcinoma Patients


Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - IPSEN SA ::EXELIXIS AND IPSEN ANNOUNCE PHASE 3 TRIAL RESULTS OF CABOZANTINIB DEMONSTRATING SIGNIFICANT OVERALL SURVIVAL BENEFIT IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA.IN CELESTIAL, CABOZANTINIB PROVIDED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT VERSUS PLACEBO IN OVERALL SURVIVAL.MEDIAN OS WAS 10.2 MONTHS WITH CABOZANTINIB VERSUS 8.0 MONTHS WITH PLACEBO. 

Company Quote

115.9
0.1 +0.09%
4:35pm BST